Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation
T. Martin, M. Sharma, L. Damon, L. Kaplan, B.J. Guglielmo, M. Working, R. O'Malley, J. Hwang, C. Linker. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2010: 12: 45–50. All r...
Gespeichert in:
| Veröffentlicht in: | Transplant infectious disease 2010-02, Vol.12 (1), p.45-50 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 50 |
|---|---|
| container_issue | 1 |
| container_start_page | 45 |
| container_title | Transplant infectious disease |
| container_volume | 12 |
| creator | Martin, T. Sharma, M. Damon, L. Kaplan, L. Guglielmo, B.J. Working, M. O'Malley, R. Hwang, J. Linker, C. |
| description | T. Martin, M. Sharma, L. Damon, L. Kaplan, B.J. Guglielmo, M. Working, R. O'Malley, J. Hwang, C. Linker. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis 2010: 12: 45–50. All rights reserved
: Seventy‐two patients undergoing allogeneic transplantation were treated with voriconazole (VOR) as antifungal prophylaxis starting from day −2 of transplantation and continuing until withdrawal of immunosuppression. Patients were assessed for safety and the incidence of definite, probable, or possible fungal infection throughout transplantation was evaluated. VOR was well tolerated. Only 14% of patients required interruption of VOR therapy because of toxicity: liver toxicity (8%), cardiac Q–T interval prolongation (1%), or other side effects (5%). In the early post‐transplant period (120 days), no patients developed probable or definite fungal infection while receiving VOR. No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective. |
| doi_str_mv | 10.1111/j.1399-3062.2009.00455.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_744598709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>744598709</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4875-6b18a83f8039be80a2c527dfcdb6257fc91d4cafb09421b708e6b3be069918c93</originalsourceid><addsrcrecordid>eNqNkV1vFCEUhidGYz_0LxjuvJopzBeQeGOq1qYbbUxbLwnDHLasDExh1u76N_zDMrubeltuOCc87wHeN8sQwQVJ62xVkIrzvMJtWZQY8wLjummKzYvs-Ong5a5meVnS6ig7iXGFMaG85q-zI8IpTww7zv7e-WCUd_KPt4BMRFFqQNL1CLQGNZnfqYtoDH6831q5SYT2AYEMdrvDrJwA6bVbSouM20m8myFr_aNxSyRTsQQHRqF7GOTkR29gSl2cYEAKrEVTkC6OVrpJzuo32SstbYS3h_00u_3y-eb8a774fnF5_nGRq5rRJm87wiSrNMMV74BhWaqmpL1WfdeWDdWKk75WUneY1yXpKGbQdlUHuOWcMMWr0-z9fm763cMa4iQGE-cHSQd-HQWt64YzimeS7UkVfIwBtBiDGWTYCoLFnIhYidl4MRsv5kTELhGxSdJ3h0vW3QD9f-EhggR82AOPxsL22YPFzeWnVCR5vpeb5OfmSS7DL9HSijbi57cLsbi-YvjH4ko01T975K0v</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>744598709</pqid></control><display><type>article</type><title>Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Martin, T. ; Sharma, M. ; Damon, L. ; Kaplan, L. ; Guglielmo, B.J. ; Working, M. ; O'Malley, R. ; Hwang, J. ; Linker, C.</creator><creatorcontrib>Martin, T. ; Sharma, M. ; Damon, L. ; Kaplan, L. ; Guglielmo, B.J. ; Working, M. ; O'Malley, R. ; Hwang, J. ; Linker, C.</creatorcontrib><description>T. Martin, M. Sharma, L. Damon, L. Kaplan, B.J. Guglielmo, M. Working, R. O'Malley, J. Hwang, C. Linker. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis 2010: 12: 45–50. All rights reserved
: Seventy‐two patients undergoing allogeneic transplantation were treated with voriconazole (VOR) as antifungal prophylaxis starting from day −2 of transplantation and continuing until withdrawal of immunosuppression. Patients were assessed for safety and the incidence of definite, probable, or possible fungal infection throughout transplantation was evaluated. VOR was well tolerated. Only 14% of patients required interruption of VOR therapy because of toxicity: liver toxicity (8%), cardiac Q–T interval prolongation (1%), or other side effects (5%). In the early post‐transplant period (<120 days), only 2 patients developed invasive fungal infection: 1 mucormycosis infection and 1 disseminated Aspergillus infection. In the late post‐transplant period (>120 days), no patients developed probable or definite fungal infection while receiving VOR. No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective.</description><identifier>ISSN: 1398-2273</identifier><identifier>EISSN: 1399-3062</identifier><identifier>DOI: 10.1111/j.1399-3062.2009.00455.x</identifier><identifier>PMID: 19793068</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adolescent ; Adult ; Aged ; allogeneic ; Antifungal Agents - adverse effects ; Antifungal Agents - therapeutic use ; Aspergillosis - drug therapy ; Aspergillosis - epidemiology ; Aspergillosis - etiology ; Aspergillosis - prevention & control ; Aspergillus ; Candida ; Candidiasis - drug therapy ; Candidiasis - epidemiology ; Candidiasis - etiology ; Candidiasis - prevention & control ; Chemoprevention ; Data processing ; Female ; fungal infections ; Heart ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunosuppression ; Incidence ; Infection ; Liver ; Male ; Middle Aged ; Mucormycosis ; Mycoses - drug therapy ; Mycoses - epidemiology ; Mycoses - etiology ; Mycoses - prevention & control ; Prophylaxis ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Side effects ; stem cell transplant ; stem cell transplantation ; Time Factors ; Toxicity ; Transplantation, Homologous - adverse effects ; Triazoles - adverse effects ; Triazoles - therapeutic use ; Voriconazole ; Young Adult</subject><ispartof>Transplant infectious disease, 2010-02, Vol.12 (1), p.45-50</ispartof><rights>2009 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4875-6b18a83f8039be80a2c527dfcdb6257fc91d4cafb09421b708e6b3be069918c93</citedby><cites>FETCH-LOGICAL-c4875-6b18a83f8039be80a2c527dfcdb6257fc91d4cafb09421b708e6b3be069918c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1399-3062.2009.00455.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1399-3062.2009.00455.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19793068$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Martin, T.</creatorcontrib><creatorcontrib>Sharma, M.</creatorcontrib><creatorcontrib>Damon, L.</creatorcontrib><creatorcontrib>Kaplan, L.</creatorcontrib><creatorcontrib>Guglielmo, B.J.</creatorcontrib><creatorcontrib>Working, M.</creatorcontrib><creatorcontrib>O'Malley, R.</creatorcontrib><creatorcontrib>Hwang, J.</creatorcontrib><creatorcontrib>Linker, C.</creatorcontrib><title>Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation</title><title>Transplant infectious disease</title><addtitle>Transpl Infect Dis</addtitle><description>T. Martin, M. Sharma, L. Damon, L. Kaplan, B.J. Guglielmo, M. Working, R. O'Malley, J. Hwang, C. Linker. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis 2010: 12: 45–50. All rights reserved
: Seventy‐two patients undergoing allogeneic transplantation were treated with voriconazole (VOR) as antifungal prophylaxis starting from day −2 of transplantation and continuing until withdrawal of immunosuppression. Patients were assessed for safety and the incidence of definite, probable, or possible fungal infection throughout transplantation was evaluated. VOR was well tolerated. Only 14% of patients required interruption of VOR therapy because of toxicity: liver toxicity (8%), cardiac Q–T interval prolongation (1%), or other side effects (5%). In the early post‐transplant period (<120 days), only 2 patients developed invasive fungal infection: 1 mucormycosis infection and 1 disseminated Aspergillus infection. In the late post‐transplant period (>120 days), no patients developed probable or definite fungal infection while receiving VOR. No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>allogeneic</subject><subject>Antifungal Agents - adverse effects</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Aspergillosis - drug therapy</subject><subject>Aspergillosis - epidemiology</subject><subject>Aspergillosis - etiology</subject><subject>Aspergillosis - prevention & control</subject><subject>Aspergillus</subject><subject>Candida</subject><subject>Candidiasis - drug therapy</subject><subject>Candidiasis - epidemiology</subject><subject>Candidiasis - etiology</subject><subject>Candidiasis - prevention & control</subject><subject>Chemoprevention</subject><subject>Data processing</subject><subject>Female</subject><subject>fungal infections</subject><subject>Heart</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Incidence</subject><subject>Infection</subject><subject>Liver</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mucormycosis</subject><subject>Mycoses - drug therapy</subject><subject>Mycoses - epidemiology</subject><subject>Mycoses - etiology</subject><subject>Mycoses - prevention & control</subject><subject>Prophylaxis</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Side effects</subject><subject>stem cell transplant</subject><subject>stem cell transplantation</subject><subject>Time Factors</subject><subject>Toxicity</subject><subject>Transplantation, Homologous - adverse effects</subject><subject>Triazoles - adverse effects</subject><subject>Triazoles - therapeutic use</subject><subject>Voriconazole</subject><subject>Young Adult</subject><issn>1398-2273</issn><issn>1399-3062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV1vFCEUhidGYz_0LxjuvJopzBeQeGOq1qYbbUxbLwnDHLasDExh1u76N_zDMrubeltuOCc87wHeN8sQwQVJ62xVkIrzvMJtWZQY8wLjummKzYvs-Ong5a5meVnS6ig7iXGFMaG85q-zI8IpTww7zv7e-WCUd_KPt4BMRFFqQNL1CLQGNZnfqYtoDH6831q5SYT2AYEMdrvDrJwA6bVbSouM20m8myFr_aNxSyRTsQQHRqF7GOTkR29gSl2cYEAKrEVTkC6OVrpJzuo32SstbYS3h_00u_3y-eb8a774fnF5_nGRq5rRJm87wiSrNMMV74BhWaqmpL1WfdeWDdWKk75WUneY1yXpKGbQdlUHuOWcMMWr0-z9fm763cMa4iQGE-cHSQd-HQWt64YzimeS7UkVfIwBtBiDGWTYCoLFnIhYidl4MRsv5kTELhGxSdJ3h0vW3QD9f-EhggR82AOPxsL22YPFzeWnVCR5vpeb5OfmSS7DL9HSijbi57cLsbi-YvjH4ko01T975K0v</recordid><startdate>201002</startdate><enddate>201002</enddate><creator>Martin, T.</creator><creator>Sharma, M.</creator><creator>Damon, L.</creator><creator>Kaplan, L.</creator><creator>Guglielmo, B.J.</creator><creator>Working, M.</creator><creator>O'Malley, R.</creator><creator>Hwang, J.</creator><creator>Linker, C.</creator><general>Blackwell Publishing Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>M7N</scope></search><sort><creationdate>201002</creationdate><title>Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation</title><author>Martin, T. ; Sharma, M. ; Damon, L. ; Kaplan, L. ; Guglielmo, B.J. ; Working, M. ; O'Malley, R. ; Hwang, J. ; Linker, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4875-6b18a83f8039be80a2c527dfcdb6257fc91d4cafb09421b708e6b3be069918c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>allogeneic</topic><topic>Antifungal Agents - adverse effects</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Aspergillosis - drug therapy</topic><topic>Aspergillosis - epidemiology</topic><topic>Aspergillosis - etiology</topic><topic>Aspergillosis - prevention & control</topic><topic>Aspergillus</topic><topic>Candida</topic><topic>Candidiasis - drug therapy</topic><topic>Candidiasis - epidemiology</topic><topic>Candidiasis - etiology</topic><topic>Candidiasis - prevention & control</topic><topic>Chemoprevention</topic><topic>Data processing</topic><topic>Female</topic><topic>fungal infections</topic><topic>Heart</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Incidence</topic><topic>Infection</topic><topic>Liver</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mucormycosis</topic><topic>Mycoses - drug therapy</topic><topic>Mycoses - epidemiology</topic><topic>Mycoses - etiology</topic><topic>Mycoses - prevention & control</topic><topic>Prophylaxis</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Side effects</topic><topic>stem cell transplant</topic><topic>stem cell transplantation</topic><topic>Time Factors</topic><topic>Toxicity</topic><topic>Transplantation, Homologous - adverse effects</topic><topic>Triazoles - adverse effects</topic><topic>Triazoles - therapeutic use</topic><topic>Voriconazole</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martin, T.</creatorcontrib><creatorcontrib>Sharma, M.</creatorcontrib><creatorcontrib>Damon, L.</creatorcontrib><creatorcontrib>Kaplan, L.</creatorcontrib><creatorcontrib>Guglielmo, B.J.</creatorcontrib><creatorcontrib>Working, M.</creatorcontrib><creatorcontrib>O'Malley, R.</creatorcontrib><creatorcontrib>Hwang, J.</creatorcontrib><creatorcontrib>Linker, C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Transplant infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martin, T.</au><au>Sharma, M.</au><au>Damon, L.</au><au>Kaplan, L.</au><au>Guglielmo, B.J.</au><au>Working, M.</au><au>O'Malley, R.</au><au>Hwang, J.</au><au>Linker, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation</atitle><jtitle>Transplant infectious disease</jtitle><addtitle>Transpl Infect Dis</addtitle><date>2010-02</date><risdate>2010</risdate><volume>12</volume><issue>1</issue><spage>45</spage><epage>50</epage><pages>45-50</pages><issn>1398-2273</issn><eissn>1399-3062</eissn><abstract>T. Martin, M. Sharma, L. Damon, L. Kaplan, B.J. Guglielmo, M. Working, R. O'Malley, J. Hwang, C. Linker. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation.
Transpl Infect Dis 2010: 12: 45–50. All rights reserved
: Seventy‐two patients undergoing allogeneic transplantation were treated with voriconazole (VOR) as antifungal prophylaxis starting from day −2 of transplantation and continuing until withdrawal of immunosuppression. Patients were assessed for safety and the incidence of definite, probable, or possible fungal infection throughout transplantation was evaluated. VOR was well tolerated. Only 14% of patients required interruption of VOR therapy because of toxicity: liver toxicity (8%), cardiac Q–T interval prolongation (1%), or other side effects (5%). In the early post‐transplant period (<120 days), only 2 patients developed invasive fungal infection: 1 mucormycosis infection and 1 disseminated Aspergillus infection. In the late post‐transplant period (>120 days), no patients developed probable or definite fungal infection while receiving VOR. No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>19793068</pmid><doi>10.1111/j.1399-3062.2009.00455.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1398-2273 |
| ispartof | Transplant infectious disease, 2010-02, Vol.12 (1), p.45-50 |
| issn | 1398-2273 1399-3062 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_744598709 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Adolescent Adult Aged allogeneic Antifungal Agents - adverse effects Antifungal Agents - therapeutic use Aspergillosis - drug therapy Aspergillosis - epidemiology Aspergillosis - etiology Aspergillosis - prevention & control Aspergillus Candida Candidiasis - drug therapy Candidiasis - epidemiology Candidiasis - etiology Candidiasis - prevention & control Chemoprevention Data processing Female fungal infections Heart Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunosuppression Incidence Infection Liver Male Middle Aged Mucormycosis Mycoses - drug therapy Mycoses - epidemiology Mycoses - etiology Mycoses - prevention & control Prophylaxis Pyrimidines - adverse effects Pyrimidines - therapeutic use Side effects stem cell transplant stem cell transplantation Time Factors Toxicity Transplantation, Homologous - adverse effects Triazoles - adverse effects Triazoles - therapeutic use Voriconazole Young Adult |
| title | Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T11%3A11%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Voriconazole%20is%20safe%20and%20effective%20as%20prophylaxis%20for%20early%20and%20late%20fungal%20infections%20following%20allogeneic%20hematopoietic%20stem%20cell%20transplantation&rft.jtitle=Transplant%20infectious%20disease&rft.au=Martin,%20T.&rft.date=2010-02&rft.volume=12&rft.issue=1&rft.spage=45&rft.epage=50&rft.pages=45-50&rft.issn=1398-2273&rft.eissn=1399-3062&rft_id=info:doi/10.1111/j.1399-3062.2009.00455.x&rft_dat=%3Cproquest_cross%3E744598709%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=744598709&rft_id=info:pmid/19793068&rfr_iscdi=true |